Skip to main
CYTK
CYTK logo

Cytokinetics (CYTK) Stock Forecast & Price Target

Cytokinetics (CYTK) Analyst Ratings

Based on 30 analyst ratings
Buy
Strong Buy 37%
Buy 53%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Cytokinetics Inc. is advancing its late-stage therapeutic pipeline, particularly with omecamtiv, which is positioned for potential regulatory approval in high-risk heart failure patients following promising trial results indicating significant treatment effects. Notably, the company has secured development partnerships with Bayer and Sanofi, enhancing its strategic positioning for the global launch of aficamten, while early preclinical data for CK-089 suggest that it could effectively improve muscle function in conditions related to muscular dystrophy. The acceptance of the Marketing Authorization Application (MAA) for aficamten signifies a critical step towards its potential global approval, further solidifying Cytokinetics’ competitive edge in the biopharmaceutical landscape.

Bears say

Cytokinetics Inc. faces significant risks that contribute to a negative outlook, including the potential for failed or inconclusive clinical trials, which could hinder the development of its investigational therapies. Additionally, the company may struggle with regulatory and commercial success, further impacting its ability to realize revenue from its drug pipeline. The challenge of securing adequate funding to advance its treatments through the development stages adds another layer of uncertainty to its financial viability.

Cytokinetics (CYTK) has been analyzed by 30 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 53% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cytokinetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cytokinetics (CYTK) Forecast

Analysts have given Cytokinetics (CYTK) a Buy based on their latest research and market trends.

According to 30 analysts, Cytokinetics (CYTK) has a Buy consensus rating as of Aug 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cytokinetics (CYTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.